Corcept Therapeutics (CORT) Tops Q3 EPS by 3c, provides guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.48 -0.13%
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $218.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $800-850 million, versus the consensus of $852.7 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Bernstein SocGen Group Reiterates Outperform Rating on Robinhood Markets (HOOD)
- Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
